SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
GEVA was delisted on the 22nd of June, 2015.
126 hedge funds and large institutions have $3.38B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2014 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 46 increasing their positions, 37 reducing their positions, and 15 closing their positions.
53% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 15
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
39% more capital invested
Capital invested by funds: $2.43B → $3.38B (+$943M)
24% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 37
5% more funds holding
Funds holding: 120 → 126 (+6)
24% less call options, than puts
Call options by funds: $9.78M | Put options by funds: $12.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$55.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$38.2M |
| 3 |
JP Morgan Chase
New York
|
+$8.91M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$7.02M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$6.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$18.8M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$11.3M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$9.99M |
| 4 |
FAM
Fred Alger Management
New York
|
-$9.77M |
| 5 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$6.31M |
GEVA Hedge Fund Activity: Q4 2014 in Review
126 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q4 2014, worth a combined $3.38B — up 39% from $2.43B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new GEVA positions and 15 closed out — a net gain of 8 holders — while 46 added to existing stakes and 37 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $55.3M. The largest seller was Sectoral Asset Management, cutting an estimated $18.8M.
- 126 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q4 2014, up from 120 in Q3 2014.
- Funds reported $3.38B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q4 2014, up 39% quarter-over-quarter.
- 23 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q4 2014 and 15 closed out, a net change of +8 holders.
- The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) buyer in Q4 2014 was Fidelity Investments, an estimated $55.3M added.
- The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q4 2014 was Sectoral Asset Management, an estimated $18.8M sold.
Based on aggregated 13F filings for Q4 2014.